Association of the insulin resistance marker triglyceride glucose index with migraine: results of a cross-sectional and prospective cohort study

Background: Type 2 diabetes has been shown to reduce the risk of migraine, whereas insulin resistance (IR) is often elevated in migraineurs. The triglyceride glucose index (TyG) serves as a reliable surrogate marker of IR, which has been hypothesized to be associated with migraine pathophysiology. This study aimed to examine the relationship between TyG index scores and incidence as well as the severity of migraines through both cohort and cross-sectional analyses. Methods: Using data from the China Health and Retirement Longitudinal Study (CHARLS), we evaluated migraine incidence between 2015 and 2020. TyG index values were calculated using the following formula: ln[fasting triglyceride (mg/dL) × fasting glucose (mg/dL)/2]. The impact of TyG index scores on the incidence of migraines was assessed using a multivariate-adjusted Cox regression model. The cross-sectional study included 161 patients with migraines in Xiamen, China. The relationship between TyG index scores and different migraine characteristics was examined using multivariable and ordered logistic regression models with further subgroup analysis by migraine course. Results: Among the cohort participants, 1001 new migraine cases were identified during follow-up, with no significant relationship found between TyG index scores and migraine incidence (hazard ratio = 1.024 (0.916, 1.145), p = 0.677 > 0.05). The cross-sectional study showed that migraine-related disability was significantly lower among patients in the second, third and fourth quartiles of TyG index scores compared to the first quartile (odds ratio = 0.402 (0.163, 0.973), 0.322 (0.128, 0.789) and 0.301 (0.119, 0.736), respectively; ptrend = 0.009). A similar trend was observed in patients with migraine history of less than ten years. Conclusions: Integrating the results of both cohort and cross-sectional studies, this study suggests that IR may play a protective role in the early stages of migraine. Further research into the relevant underlying mechanisms could aid in identifying new therapeutic targets for migraine management.

Chinese population; Migraine incidence; Migraine disability; Triglyceride glucose index; Insulin resistance

[1] Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, et al. Migraine: epidemiology and systems of care. The Lancet. 2021; 397: 1485–1495.

[2] Ge R, Chang J. Disease burden of migraine and tension-type headache in non-high-income East and Southeast Asia from 1990 to 2019. The Journal of Headache and Pain. 2023; 24: 32.

[3] Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, et al. Migraine. Nature Reviews Disease Primers. 2022; 8: 2.

[4] Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T, et al. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. The Journal of Headache and Pain. 2022; 23: 146.

[5] Fagherazzi G, El Fatouhi D, Fournier A, Gusto G, Mancini FR, Balkau B, et al. Associations between migraine and Type 2 diabetes in women: findings from the E3N cohort study. JAMA Neurology. 2019; 76: 257–263.

[6] Antonazzo IC, Riise T, Cortese M, Berge LI, Engeland A, Bernt Fasmer O, et al. Diabetes is associated with decreased migraine risk: a nationwide cohort study. Cephalalgia. 2018; 38: 1759–1764.

[7] Wu J, Fang J, Yuan X, Ma L, Zheng L, Lin Q, et al. Associations of type 2 diabetes and the risk of migraine in Chinese populations. Diabetes & Metabolism Journal. 2024; 50: 101518.

[8] Islam MR, The International Headache Genetics Consortium Ihgc, Nyholt DR. Genetic overlap analysis identifies a shared etiology between migraine and headache with type 2 diabetes. Genes. 2022; 13: 1845.

[9] Islam MR; International Headache Genetics Consortium (IHGC); Nyholt DR. Cross-trait analyses identify shared genetics between migraine, headache, and glycemic traits, and a causal relationship with fasting proinsulin. Human Genetics. 2023; 142: 1149–1172.

[10] Rainero I, Limone P, Ferrero M, Valfrè W, Pelissetto C, Rubino E, et al. Insulin sensitivity is impaired in patients with migraine. Cephalalgia. 2005; 25: 593–597.

[11] Cavestro C, Rosatello A, Micca G, Ravotto M, Marino MP, Asteggiano G, et al. Insulin metabolism is altered in migraineurs: a new pathogenic mechanism for migraine? Headache. 2007; 47: 1436–1442.

[12] Bhoi SK, Kalita J, Misra UK. Metabolic syndrome and insulin resistance in migraine. The Journal of Headache and Pain. 2012; 13: 321–326.

[13] Sacco S, Altobelli E, Ornello R, Ripa P, Pistoia F, Carolei A. Insulin resistance in migraineurs: results from a case-control study. Cephalalgia. 2014; 34: 349–356.

[14] Fava A, Pirritano D, Consoli D, Plastino M, Casalinuovo F, Cristofaro S, et al. Chronic migraine in women is associated with insulin resistance: a cross-sectional study. European Journal of Neurology. 2014; 21: 267–272.

[15] Siva ZO, Uluduz D, Keskin FE, Erenler F, Balcı H, Uygunoğlu U, et al. Determinants of glucose metabolism and the role of NPY in the progression of insulin resistance in chronic migraine. Cephalalgia. 2018; 38: 1773–1781.

[16] Ali M, Hussein M, Magdy R, Khamis A, Al-Azayem SA, Othman AM, et al. The potential impact of insulin resistance and metabolic syndrome on migraine headache characteristics. BMC Neurology. 2022; 22: 422.

[17] Rainero I, Govone F, Gai A, Vacca A, Rubino E. Is migraine primarily a metaboloendocrine disorder? Current Pain and Headache Reports. 2018; 22: 36.

[18] Del Moro L, Rota E, Pirovano E, Rainero I. Migraine, brain glucose metabolism and the “neuroenergetic” hypothesis: a scoping review. The Journal of Pain. 2022; 23: 1294–1317.

[19] Irace C, Carallo C, Scavelli FB, De Franceschi MS, Esposito T, Tripolino C, et al. Markers of insulin resistance and carotid atherosclerosis. A comparison of the homeostasis model assessment and triglyceride glucose index. International Journal of Clinical Practice. 2013; 67: 665–672.

[20] Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. The Journal of Clinical Endocrinology & Metabolism. 2010; 95: 3347–3351.

[21] Zou S, Yang C, Shen R, Wei X, Gong J, Pan Y, et al. Association between the triglyceride-glucose index and the incidence of diabetes in people with different phenotypes of obesity: a retrospective study. Frontiers in Endocrinology. 2021; 12: 784616.

[22] Park HM, Lee HS, Lee YJ, Lee JH. The triglyceride-glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistance. Diabetes Research and Clinical Practice. 2021; 180: 109042.

[23] Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovascular Diabetology. 2022; 21: 68.

[24] Huang Z, Ding X, Yue Q, et al. Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study. Cardiovascular Diabetology. 2022; 21: 141.

[25] Hong S, Han K, Park CY. The insulin resistance by triglyceride glucose index and risk for dementia: population-based study. Alzheimer’s Research & Therapy. 2021; 13: 9.

[26] Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS). International Journal of Epidemiology. 2014; 43: 61–68.

[27] Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38: 1–211.

[28] Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metabolic Syndrome and Related Disorders. 2008; 6: 299–304.

[29] Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology. 2003; 61: 375–382.

[30] Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56: S20–S28.

[31] Liu Y, Gao X, Yuan L, Li Y, Hong P. The relationship between triglyceride glucose index and migraine: a cross-section study from the national health and nutrition examination survey (NHANES). Current Neurovascular Research. 2023; 20: 230–236.

[32] Gur-Ozmen S, Karahan-Ozcan R. Factors associated with insulin resistance in women with migraine: a cross-sectional study. Pain Medicine. 2019; 20: 2043–2050.

[33] Park B, Lee HS, Lee YJ. Triglyceride glucose (TyG) index as a predictor of incident type 2 diabetes among nonobese adults: a 12-year longitudinal study of the Korean Genome and Epidemiology Study cohort. Translational Research. 2021; 228: 42–51.

[34] Xu X, Huang R, Lin Y, Guo Y, Xiong Z, Zhong X, et al. High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study. Cardiovascular Diabetology. 2022; 21: 155.

[35] Wang J, Huang X, Fu C, Sheng Q, Liu P. Association between triglyceride glucose index, coronary artery calcification and multivessel coronary disease in Chinese patients with acute coronary syndrome. Cardiovascular Diabetology. 2022; 21: 187.

[36] Wang X, Xu W, Song Q, Zhao Z, Meng X, Xia C, et al. Association between the triglyceride-glucose index and severity of coronary artery disease. Cardiovascular Diabetology. 2022; 21: 168.

[37] Borkum JM. Brain energy deficit as a source of oxidative stress in migraine: a molecular basis for migraine susceptibility. Neurochemical Research. 2021; 46: 1913–1932.

[38] Fila M, Chojnacki C, Chojnacki J, Blasiak J. Nutrients to improve mitochondrial function to reduce brain energy deficit and oxidative stress in migraine. Nutrients. 2021; 13: 4433.

[39] Liu H, Wang L, Chen C, Dong Z, Yu S. Association between dietary niacin intake and migraine among American adults: national health and nutrition examination survey. Nutrients. 2022; 14: 3052.

[40] Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine - from pathophysiology to treatment. Nature Reviews Neurology. 2019; 15: 627–643.

[41] Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019; 576: 51–60.

[42] Ekici B, Unal-Cevik I, Akgul-Ercan E, Morkavuk G, Yakut Y, Erkan AF. Duration of migraine is associated with cardiac diastolic dysfunction. Pain Medicine. 2013; 14: 988–993.

[43] Gossrau G, Frost M, Klimova A, Koch T, Sabatowski R, Mignot C, et al. Interictal osmophobia is associated with longer migraine disease duration. The Journal of Headache and Pain. 2022; 23: 81.

[44] Amouroux R, Rousseau-Salvador C, Pillant M, Antonietti JP, Tourniaire B, Annequin D. Longitudinal study shows that depression in childhood is associated with a worse evolution of headaches in adolescence. Acta Paediatrica. 2017; 106: 1961–1965.

[45] Fang J, Wu J, Zhang T, Yuan X, Zhao J, Zheng L, et al. Serum neurofilament light chain levels in migraine patients: a monocentric case-control study in China. The Journal of Headache and Pain. 2023; 24: 149.

[46] Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiological Reviews. 2017; 97: 553–622.